Inspiration Biopharmaceuticals, Inc. ("Inspiration")
rFIX (recombinant Factor IX)
Hemophilia B
rFIX is in human clinical trials for the treatment of Hemophilia B
Celtic Pharma owns a direct economic interest in Inspiration’s lead product, rFIX, and in addition, Celtic owns shares in Inspiration. Inspiration is focused on developing innovative recombinant blood coagulation factor products to fundamentally change the treatment of hemophilia. Inspiration uses advanced manufacturing technologies with increased productivity which significantly lowers the production costs of Factor products compared with existing manufacturing processes. The Company plans to develop multiple products for hemophilia and coagulation disorders, including:
- Factor IX (Hemophilia B)
- Factor VIII (Hemophilia A)
- Factor VIIa (Hemophilia A&B)